Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660699 · ClinicalTrials.gov registry record · Phase 2
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00660699 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 50 participants.
The verdict
NCT00660699, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
To assess the feasibility of administering induction chemotherapy with gemcitabine and docetaxel followed by concurrent radiation and continuous infusion 5FU and consolidation gemcitabine/docetaxel chemotherapy.
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660699
The ClinicalTrials.gov registry entry for NCT00660699 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00660699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660699 about?
NCT00660699 is a clinical study titled "A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers". To assess the feasibility of administering induction chemotherapy with gemcitabine and docetaxel followed by concurrent radiation and continuous infusion 5FU and consolidation gemcitabine/docetaxel chemotherapy.
What is the current status of trial NCT00660699?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2002-09. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00660699?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT00660699?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.